Monotherapy with nivolumab, a PD-1-targeting mAb, although associated with a favorable safety profile, exhibited a low ORR among DLBCL patients who were ineligible or failed the AHSCT. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.